2.An audit of transmucosal immediate-release fentanyl prescribing at a university hospital
Shinsuke Hara ; Isseki Maeda ; Yoichi Matsuda ; Yumiko Ohno ; Hitoshi Tanimukai ; Satoru Tsuneto ; Hiroko Kadowaki ; Manabu Takegami ; Yoshihiro Miwa
Palliative Care Research 2015;10(1):107-112
Transmucosal Immediate-Release Fentanyl(TIRF)can be a key-drug for breakthrough cancer pain. Prescription audit is needed because there are concerns about tolerance or serious adverse events including respiratory suppression and addiction due to inappropriate use of these drugs. The aim of this audit study is to evaluate appropriateness of TIRF prescriptions, reasons of violation, and adverse events in the real-world setting. A retrospective chart review was conducted in 31 patients who had breakthrough cancer pain and were treated with TIRF. A 2-step algorithm was generated:baseline pain and administration situation of other opioid rescues. TIRF was prescribed appropriately in six patients(19.4%). Reasons of violation were as follows:prescriptions only for using same drug with around-the-clock opioids(fentanyl transdermal patches, n=19), and patients could take oral medicines and use of morphine or oxycodone rescues would be preferable(n=12). TIRF was initiated with a minimum dose in all patients and no serious adverse events were observed. Although TIRF was used widely for breakthrough cancer pain, prescription was not necessarily done appropriately. Detailed assessment of breakthrough cancer pain and consideration of the use the other rescue medication would be required.
3.Reduction of oocyte lipid droplets and meiotic failure due to biotin deficiency was not rescued by restoring the biotin nutritional status
Ai TSUJI ; Yuka IKEDA ; Mutsumi MURAKAMI ; Yasuko KITAGISHI ; Satoru MATSUDA
Nutrition Research and Practice 2022;16(3):314-329
BACKGROUND/OBJECTIVES:
Oocyte lipid droplets play a crucial role in meiosis and embryo development. Biotin is associated with fatty acid synthesis and is the coenzyme for acetyl-CoA carboxylase (ACC). The effects of a biotin deficiency on the oocyte lipid metabolism remain unknown. This study examined the effects of a biotin deficiency and its replenishment on murine 1) oocyte lipid droplet levels, 2) ovary lipid metabolism, and 3) oocyte meiosis.MATERIALS/METHODS: Mice were divided into 3 groups: control, biotin deficient (BD), and recovery groups. The control and BD groups were fed a control diet or BD diet (0.004 or 0 g biotin/kg), respectively. The recovery group mice were fed a BD diet until day 21, and were then fed the control diet from days 22 to 64. This study then quantified the oocyte lipid droplet levels, assessed the oocyte mitochondrial function, and examined the ability of oocytes to undergo meiosis. Ovarian phosphorylated ACC (p-ACC), lipogenesis, β-oxidation, and ATP production-related genes were evaluated.
RESULTS:
The BD group showed a decrease in lipid droplets and mitochondrial membrane potential and increased p-ACC levels. In the recovery group, the hepatic biotin concentration, ovarian p-ACC levels, and mitochondrial membrane potential were restored to the control group levels. On the other hand, the quantity of lipid droplets in the recovery group was not restored to the control levels. Furthermore, the percentage of oocytes with meiotic abnormalities was higher in the recovery group than in the control group.
CONCLUSIONS
A biotin deficiency reduced the oocyte lipid droplet levels by downregulating lipogenesis. The decreased lipid droplets and increased oocyte meiosis failure were not fully restored, even though the biotin nutrition status and gene expression of lipid metabolism was resumed. These results suggest that a biotin deficiency remains robust and can be longlasting. Biotin might play a crucial role in maintaining the oocyte quality.
4.Efficacy of Current Traction Techniques for Endoscopic Submucosal Dissection
Seiichiro ABE ; Shih Yea SYLVIA WU ; Mai EGO ; Hiroyuki TAKAMARU ; Masau SEKIGUCHI ; Masayoshi YAMADA ; Satoru NONAKA ; Taku SAKAMOTO ; Haruhisa SUZUKI ; Shigetaka YOSHINAGA ; Takahisa MATSUDA ; Ichiro ODA ; Yutaka SAITO
Gut and Liver 2020;14(6):673-684
This systematic review aimed to assess the efficacy of the current approach to tissue traction during the endoscopic submucosal dissection (ESD) of superficial esophageal cancer, early gastric cancer, and colorectal neoplasms.We performed a systematic electronic literature search of articles published in PubMed and selected comparative studies to investigate the treatment outcomes of tractionassisted versus conventional ESD. Using the keywords, we retrieved 381 articles, including five eligible articles on the esophagus, 13 on the stomach, and 12 on the colorectum. A total of seven randomized controlled tri-als and 23 retrospective studies were identified. Clip line traction and submucosal tunneling were effective in re-ducing the procedural time during esophageal ESD. The efficacy of traction methods in gastric ESD varied in terms of the devices and strategies used depending on the le-sion location and degree of submucosal fibrosis. Several prospective and retrospective studies utilized traction de-vices without the need to reinsert the colonoscope. When pocket creation is included, the traction devices and methods effectively shorten the procedural time during colorectal ESD. Although the efficacy is dependent on the organ and tumor locations, several traction techniques have been demonstrated to be efficacious in facilitating ESD by maintaining satisfactory traction during dissection.
5.Reduced Intravenous Fluorescein Dose for Upper and Lower Gastrointestinal Tract Probe-Based Confocal Laser Endomicroscopy
Kazuya INOKI ; Seiichiro ABE ; Yusaku TANAKA ; Koji YAMAMOTO ; Daisuke HIHARA ; Ryoji ICHIJIMA ; Yukihiro NAKATANI ; HsinYu CHEN ; Hiroyuki TAKAMARU ; Masau SEKIGUCHI ; Masayoshi YAMADA ; Taku SAKAMOTO ; Satoru NONAKA ; Haruhisa SUZUKI ; Shigetaka YOSHINAGA ; Ichiro ODA ; Takahisa MATSUDA ; Yutaka SAITO
Clinical Endoscopy 2021;54(3):363-370
Background/Aims:
Probe-based confocal laser endomicroscopy (pCLE) requires the administration of intravenous (IV) fluorescein. This study aimed to determine the optimal dose of IV fluorescein for both upper and lower gastrointestinal (GI) tract pCLE.
Methods:
Patients 20 to 79 years old with gastric high-grade dysplasia (HGD) or colorectal neoplasms (CRNs) were enrolled in the study. The dose de-escalation method was employed with five levels. The primary endpoint of the study was the determination of the optimal dose of IV fluorescein for pCLE of the GI tract. The reduced dose was determined based on off-line reviews by three endoscopists. An insufficient dose of fluorescein was defined as the dose of fluorescein with which the pCLE images were not deemed to be visible. If all three endoscopists determined that the tissue structure was visible, the doses were de-escalated.
Results:
A total of 12 patients with gastric HGD and 12 patients with CRNs were enrolled in the study. Doses were de-escalated to 0.5 mg/kg of fluorescein for both non-neoplastic duodenal and colorectal mucosa. All gastric HGD or CRNs were visible with pCLE with IV fluorescein at 0.5 mg/kg.
Conclusions
In the present study, pCLE with IV fluorescein 0.5 mg/kg was adequate to visualize the magnified structure of both the upper and lower GI tract.
6.Reduced Intravenous Fluorescein Dose for Upper and Lower Gastrointestinal Tract Probe-Based Confocal Laser Endomicroscopy
Kazuya INOKI ; Seiichiro ABE ; Yusaku TANAKA ; Koji YAMAMOTO ; Daisuke HIHARA ; Ryoji ICHIJIMA ; Yukihiro NAKATANI ; HsinYu CHEN ; Hiroyuki TAKAMARU ; Masau SEKIGUCHI ; Masayoshi YAMADA ; Taku SAKAMOTO ; Satoru NONAKA ; Haruhisa SUZUKI ; Shigetaka YOSHINAGA ; Ichiro ODA ; Takahisa MATSUDA ; Yutaka SAITO
Clinical Endoscopy 2021;54(3):363-370
Background/Aims:
Probe-based confocal laser endomicroscopy (pCLE) requires the administration of intravenous (IV) fluorescein. This study aimed to determine the optimal dose of IV fluorescein for both upper and lower gastrointestinal (GI) tract pCLE.
Methods:
Patients 20 to 79 years old with gastric high-grade dysplasia (HGD) or colorectal neoplasms (CRNs) were enrolled in the study. The dose de-escalation method was employed with five levels. The primary endpoint of the study was the determination of the optimal dose of IV fluorescein for pCLE of the GI tract. The reduced dose was determined based on off-line reviews by three endoscopists. An insufficient dose of fluorescein was defined as the dose of fluorescein with which the pCLE images were not deemed to be visible. If all three endoscopists determined that the tissue structure was visible, the doses were de-escalated.
Results:
A total of 12 patients with gastric HGD and 12 patients with CRNs were enrolled in the study. Doses were de-escalated to 0.5 mg/kg of fluorescein for both non-neoplastic duodenal and colorectal mucosa. All gastric HGD or CRNs were visible with pCLE with IV fluorescein at 0.5 mg/kg.
Conclusions
In the present study, pCLE with IV fluorescein 0.5 mg/kg was adequate to visualize the magnified structure of both the upper and lower GI tract.